top of page

Sage Therapeutics Announces Topline Results from the Phase 2 SURVEYOR Study.

  • katrina4384
  • Jun 11, 2024
  • 1 min read


"The study met its primary endpoint, demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD_CAB) composite score at baseline between healthy participants with Huntington's Disease (HD) prior to any treatment with dalzanemdor (SAGE-718) or placebo."


 
 
 

Comments


Subscribe Form

  • facebook
  • instagram
  • twitter

©2022 by Help 4 HD International. Proudly created with Wix.com

bottom of page